BMY:US
$48.18
3.724%

Bristol-Myers Squibb Company
News & Events

Last updated: May 12, 2025, 4:41 PM ET

  1. Improving Access to Care by Strengthening Local Health System Capacity

    ACCESS Newswire MAY 7, 2025 9:45 AM EDT
    NORTHAMPTON, MA / ACCESS Newswire / May 7, 2025 / By Catharine Grimes , President of the Bris...
    READ ARTICLE
  2. Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

    Business Wire MAY 6, 2025 6:59 AM EDT
    Gallman’s Appointment is Effective Immediately Sandra Leung, Executive Vice Presid...
    READ ARTICLE
  3. Bristol Myers Squibb Reports First Quarter Financial Results for 2025

    Business Wire APR 24, 2025 6:59 AM EDT
    Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution First qua...
    READ ARTICLE
  4. Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

    Business Wire APR 22, 2025 4:15 PM EDT
    Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a...
    READ ARTICLE
  5. U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

    Business Wire APR 17, 2025 8:21 PM EDT
    Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients i...
    READ ARTICLE
  6. Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

    Business Wire APR 14, 2025 4:15 PM EDT
    Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Cam...
    READ ARTICLE
  7. U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

    Business Wire APR 11, 2025 3:49 PM EDT
    Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically...
    READ ARTICLE
  8. U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

    Business Wire APR 8, 2025 3:36 PM EDT
    Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in th...
    READ ARTICLE
  9. Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...

    Business Wire MAR 28, 2025 8:53 AM EDT
    Recommendation based on Phase 3 CheckMate -77T trial showing significant event-free survival ...
    READ ARTICLE
  10. Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

    Business Wire MAR 28, 2025 8:00 AM EDT
    Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which ...
    READ ARTICLE

Upcoming Events

Get notified of Bristol-Myers Squibb Company’s latest announcements, news, and event dates.
  • Upcoming earnings announcement (Estimated)

    Jul 31, 2025
  • Upcoming dividend payout

    Not Available
  • Upcoming stock splits

    Not Available